CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CING CINGULATE INC.

Post-Market Trading 11-26 19:16:08 EST

4.36

-0.34

-7.23%

盘后4.31

-0.05-1.15%

17:41 EST

High4.61	Low4.30	Vol63.66K
Open4.48	D1 Closing4.70	Amplitude6.60%
Mkt Cap14.01M	Tradable Cap13.97M	Total Shares3.21M
T/O285.00K	T/O Rate1.99%	Tradable Shares3.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CING","market":"US","secType":"STK","nameCN":"CINGULATE INC.","latestPrice":4.36,"timestamp":1732654800000,"preClose":4.7,"halted":0,"volume":63656,"hourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.36,"latestTime":"17:41 EST","volume":475,"amount":2068.3514,"timestamp":1732660907787},"delay":0,"floatShares":3203100,"shares":3212233,"eps":-24.458035,"marketStatus":"Post-Market Trading","change":-0.34,"latestTime":"11-26 19:16:08 EST","open":4.48,"high":4.61,"low":4.3,"amount":285003.50772,"amplitude":0.065957,"askPrice":4.54,"askSize":50,"bidPrice":4.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-24.458035,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732669200000},"marketStatusCode":4,"adr":0,"listingDate":1633579200000,"exchange":"NASDAQ","adjPreClose":4.7,"preHourTrading":{"tag":"盘前","latestPrice":4.52,"preClose":4.7,"latestTime":"09:27 EST","volume":586,"amount":2658.4596716,"timestamp":1732631254837},"postHourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.36,"latestTime":"17:41 EST","volume":475,"amount":2068.3514,"timestamp":1732660907787},"volumeRatio":0.398609},"requestUrl":"/m/hq/s/CING/wiki","defaultTab":"wiki","newsList":[{"id":"2485141841","title":"Cingulate Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2485141841","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485141841?lang=en_us&edition=fundamental","pubTime":"2024-11-21 00:12","pubTimestamp":1732119120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 11:12 ET (16:12 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING"],"gpt_icon":0},{"id":"2484113694","title":"Maxim Group Upgrades Cingulate to Buy From Neutral, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113694","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484113694?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:53","pubTimestamp":1732107229,"startTime":"0","endTime":"0","summary":"Maxim Group Upgrades Cingulate to Buy From Neutral, $8 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CING"],"gpt_icon":0},{"id":"2482859780","title":"CING: Third Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482859780","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482859780?lang=en_us&edition=fundamental","pubTime":"2024-11-12 16:15","pubTimestamp":1731399300,"startTime":"0","endTime":"0","summary":"Cingulate, Inc.  reported third quarter results on November 7th, 2024. No revenues were reported and operating expense of $3.3 million was recognized. During the third quarter and to date the company was issued a European patent for tripulse stimulant formulations, participated in multiple business media interviews and started its final study for CTx-1301 required for the new drug application . The NDA is expected to be submitted in mid-2025. Cingulate was also able to raise additional capital through its At-the-Market  facility and other arrangements, increasing its end of quarter cash balance to over $10 million.Cingulate reported third quarter 2024 results in a press release and Form 10-Q filing with the SEC on November 7th. For the quarter ending September 30, 2024 operating expenses of $3.3 million were recognized. Net loss for 3Q:24 totaled  million or  per share. For the third quarter of 2024 versus the same prior year period:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cing-third-quarter-results-081500584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CINGW","BK4007","BK4139","ABVC","CING"],"gpt_icon":0},{"id":"2481906029","title":"Cingulate Q3 Net Loss $3.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481906029","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481906029?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:41","pubTimestamp":1730983289,"startTime":"0","endTime":"0","summary":"Cingulate Q3 Net Loss $3.2M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41804447/cingulate-q3-net-loss-3-2m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2481905055","title":"Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance Adhd Drug to Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481905055?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA6QT3BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING","CINGW"],"gpt_icon":0},{"id":"2481069199","title":"Press Release: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2481069199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481069199?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982600,"startTime":"0","endTime":"0","summary":"Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market. On Target for Mid-2025 New Drug Application  Submission of lead ADHD asset CTx-1301. \"The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025,\" said Cingulate Chairman and CEO Shane J. Schaffer. \"The granting of European patents for CTx-1301 in up to 30 territories, including the United Kingdom, helps Cingulate expand its reach beyond the United States and makes a positive impact on the growing ADHD markets abroad. Overall, Cingulate finds itself in a stronger position financially and looks forward to filing its first NDA next year.\". In September, Cingulate commenced its final FDA-required study, which is a food effect study, for CTx-1301. A data readout from the study is expected by the end of 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4585","BK4232","NQmain","03160","BK4099","ABVC","BK4139","TM","CING","ADHD","WRD","BK4588","BK4007","BK4022","BK4555"],"gpt_icon":0},{"id":"2474282407","title":"Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show","url":"https://stock-news.laohu8.com/highlight/detail?id=2474282407","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474282407?lang=en_us&edition=fundamental","pubTime":"2024-10-09 03:15","pubTimestamp":1728414900,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., Oct.  08, 2024  (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Relea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/08/2960091/0/en/Cingulate-s-Shane-Schaffer-Joins-Cast-of-Nationally-Syndicated-Big-Biz-Show.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007","ADHD"],"gpt_icon":0},{"id":"2473970759","title":"BRIEF-Cingulate CEO Shane Schaffer Was Charged With One Count Of \"Aggravated Domestic Battery\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2473970759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473970759?lang=en_us&edition=fundamental","pubTime":"2024-10-05 04:45","pubTimestamp":1728074700,"startTime":"0","endTime":"0","summary":"Oct 4 (Reuters) - Cingulate Inc   :   * CINGULATE INC: ON SEPT 23, SHANE SCHAFFER, CEO & CHAIRMAN OF CO WAS CHARGED WITH ONE COUNT OF \"AGGRAVATED DOMESTIC BATTERY\"Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2473997531","title":"Cingulate Inc: on Sept 23, Shane Schaffer, CEO & Chairman of Co Was Charged With One Count of \"Aggravated Domestic Battery\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2473997531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473997531?lang=en_us&edition=fundamental","pubTime":"2024-10-05 04:35","pubTimestamp":1728074102,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241004:nFWN3LG0ST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2470244703","title":"Cingulate files to sell 1.5M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2470244703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470244703?lang=en_us&edition=fundamental","pubTime":"2024-09-27 18:30","pubTimestamp":1727433022,"startTime":"0","endTime":"0","summary":"06:25 EDT Cingulate files to sell 1.5M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-1-5m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-files-to-sell-1-5m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2470703583","title":"Cingulate Inc Files for Resale of up to 1.5 Mln Shares by the Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2470703583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470703583?lang=en_us&edition=fundamental","pubTime":"2024-09-27 18:25","pubTimestamp":1727432745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240927:nFWN3L81GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2469111111","title":"BRIEF-MedCerts Launches Certified Cing Assistant eLearning Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2469111111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469111111?lang=en_us&edition=fundamental","pubTime":"2024-09-23 21:25","pubTimestamp":1727097951,"startTime":"0","endTime":"0","summary":"Sept 23 (Reuters) - Stride Inc   :   * MEDCERTS LAUNCHES CERTIFIED CING ASSISTANT (CNA) ELEARNING PROGRAM BENEFITING MEDICAL PROVIDERS, PATIENTS AND ASPIRING HEALTHCARE PROFESSIONALSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","IE0009354923.USD","LU2517655291.USD","BK4107","BK4204","CNA","LU2517655028.SGD","LU2362541513.USD","BK4007","CING","LU2517655374.HKD","LU2362540622.SGD","LRN"],"gpt_icon":0},{"id":"2469180111","title":"MedCerts Launches Certified Cing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals","url":"https://stock-news.laohu8.com/highlight/detail?id=2469180111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469180111?lang=en_us&edition=fundamental","pubTime":"2024-09-23 20:00","pubTimestamp":1727092800,"startTime":"0","endTime":"0","summary":"New certification program features generative and conversational AI developed in-house, setting a new standard in healthcare training. The program's AI-based characters respond like humans - based on pre-loaded context and data defined by us. LIVONIA, Mich., Sept. 23, 2024  -- Offering a vital solution for healthcare providers requiring more trained personnel and patients in need of qualified care, MedCerts today announced the launch of its Certified Nursing Assistant  eLearning program. The multi-week immersive course features generative and conversational AI, pioneered by MedCerts, establishing a new benchmark in healthcare training while addressing urgent staffing needs. MedCerts is known for its innovation in online career training in allied healthcare and information technology programs.“We are excited to launch our Certified Nursing Assistant program, which we developed to meet the needs of healthcare providers and patients while opening new doors for aspiring healthcare professi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/E5TAYg1Jj2r.mkwJkhApOw--~B/aD0xMDc5O3c9MTkxOTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ba103ba65ff2b6855832d55a533c0adf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/E5TAYg1Jj2r.mkwJkhApOw--~B/aD0xMDc5O3c9MTkxOTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ba103ba65ff2b6855832d55a533c0adf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medcerts-launches-certified-cing-assistant-120000924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","LU2517655291.USD","IE0009354923.USD","LRN","LU2362541273.HKD","BK4204","CING","LU2362541513.USD","BK4137","LU2517655028.SGD","LU2517655374.HKD","CNA","LU2362540622.SGD","BK4007","BK4107"],"gpt_icon":0},{"id":"2466277455","title":"Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched","url":"https://stock-news.laohu8.com/highlight/detail?id=2466277455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466277455?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:59","pubTimestamp":1726145943,"startTime":"0","endTime":"0","summary":"An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. has reinstated the pre-cut salaries of its top executives and conti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-executive-pay-restored-funding-up-fda-study-launched?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-inc-executive-pay-restored-funding-up-fda-study-launched?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2466274111","title":"Cingulate Inc:  Initiates Final Study for Lead Adhd Asset Ctx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2466274111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466274111?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:33","pubTimestamp":1726144437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU13M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2466746292","title":"Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2466746292","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466746292?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:30","pubTimestamp":1726144200,"startTime":"0","endTime":"0","summary":"$10 Million of additional Capital Recently Raised Strengthening Balance Sheet. KANSAS CITY, Kan., Sept. 12, 2024  -- Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has commenced its final FDA-required study, which is a food effect study, for CTx-1301  for the treatment of Attention Deficit Hyperactivity Disorder . A data readout from the study is expected by the end of 2024.About CTx-1301Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. W","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y0lYCPliWOSvK4uC8u5_iQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/abb1e4a13fcd9794394ef0325acbce45","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y0lYCPliWOSvK4uC8u5_iQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/abb1e4a13fcd9794394ef0325acbce45"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cingulate-initiates-final-study-lead-123000977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CING","BK4007","CINGW","ADHD","ABVC"],"gpt_icon":0},{"id":"2462457149","title":"Cingulate to Participate in Benzinga All Live Access Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2462457149","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462457149?lang=en_us&edition=fundamental","pubTime":"2024-08-28 04:30","pubTimestamp":1724790600,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., Aug.  27, 2024  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/27/2936632/0/en/Cingulate-to-Participate-in-Benzinga-All-Live-Access-Event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADHD","CING"],"gpt_icon":0},{"id":"2462916412","title":"CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2462916412","media":"Zacks Small Cap Research","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462916412?lang=en_us&edition=fundamental","pubTime":"2024-08-26 17:41","pubTimestamp":1724665260,"startTime":"0","endTime":"0","summary":"We are initiating coverage of Cingulate, Inc.  with a target price of $70.00 per share. This value is based on our forecasts for the successful development and commercialization of CTx-1301 for Attention Deficit/ Hyperactivity Disorder . Cingulate’s candidate uses its licensed precision timed release  platform to deliver drugs in indications which require a particular release profile over an extended period of up to 24 hours. Its lead indication in ADHD seeks to address a disorder marked by a persistent pattern of inattention, hyperactivity, and/or impulsivity that interferes with sustaining focus and staying organized. Prevalence is estimated to be from 11 to 15% in children and from 4 – 5% in adults. Males are more commonly diagnosed than females.Assuming CTx-1301 is approved, Cingulate has several options for commercialization. The company has a non-binding arrangement with Indegene to commercialize the p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3Et6UoSIyTqprIoS6SOxDA--~B/aD04NTg7dz0xNzk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/3fa2ae7bbc6ddafef04af3a7a26ebf73","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3Et6UoSIyTqprIoS6SOxDA--~B/aD04NTg7dz0xNzk2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/3fa2ae7bbc6ddafef04af3a7a26ebf73"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cing-initiating-coverage-precision-timed-094100329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["API","BK4023","BK4551","IPO","ADHD","ABVC","BK4503","BK4139","DCF","CING","BK4535","BK4007"],"gpt_icon":1},{"id":"2461240565","title":"BRIEF-Cingulate Announces Adjournment Of Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2461240565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461240565?lang=en_us&edition=fundamental","pubTime":"2024-08-24 06:20","pubTimestamp":1724451601,"startTime":"0","endTime":"0","summary":"Aug 23 (Reuters) - Cingulate Inc   :   * CINGULATE ANNOUNCES ADJOURNMENT OF SPECIAL MEETINGSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2461523255","title":"Cingulate Announces Adjournment of Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2461523255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461523255?lang=en_us&edition=fundamental","pubTime":"2024-08-24 04:45","pubTimestamp":1724445904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240823:nFWN3KA0ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CING"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cingulate.com","stockEarnings":[{"period":"1week","weight":0.1692},{"period":"1month","weight":0.0755},{"period":"3month","weight":-0.5243},{"period":"6month","weight":-0.4405},{"period":"1year","weight":-0.9452},{"period":"ytd","weight":-0.9488}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.32126},{"month":2,"riseRate":0.333333,"avgChangeRate":0.023356},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.084752},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.082482},{"month":5,"riseRate":0,"avgChangeRate":-0.240081},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.060694},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.164627},{"month":8,"riseRate":1,"avgChangeRate":0.47866},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.202848},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.194193},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.062799},{"month":12,"riseRate":1,"avgChangeRate":0.113725}],"exchange":"NASDAQ","name":"CINGULATE INC.","nameEN":"CINGULATE INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CINGULATE INC.,CING,CINGULATE INC.股票,CINGULATE INC.股票老虎,CINGULATE INC.股票老虎国际,CINGULATE INC.行情,CINGULATE INC.股票行情,CINGULATE INC.股价,CINGULATE INC.股市,CINGULATE INC.股票价格,CINGULATE INC.股票交易,CINGULATE INC.股票购买,CINGULATE INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}